Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifungal chemotherapy.

M H Koldin, G Medoff

    Pediatric Clinics of North America
    |February 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Amphotericin B (AmB) is the primary treatment for systemic fungal infections. Miconazole and ketoconazole offer alternatives for specific cases, while 5-fluorocytosine (5-FC) is best used with AmB for yeast infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1999
    Same author

    New challenges to the therapy of systemic fungal infections.

    Transactions of the American Clinical and Climatological Association·1995
    Same author

    Screening of physicians for tuberculosis.

    Infection control and hospital epidemiology·1994
    Same author

    Evaluation of rooms with negative pressure ventilation used for respiratory isolation in seven midwestern hospitals.

    Infection control and hospital epidemiology·1993
    Same author

    Results of a rubella screening program for hospital employees: a five-year review (1986-1990).

    American journal of epidemiology·1993
    Same author

    Formulary control of antimicrobial usage. What price freedom?

    Diagnostic microbiology and infectious disease·1993
    Same journal

    Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

    Pediatric clinics of North America·2026
    Same journal

    Advancing Pediatric Dermatology: Innovations in Care and Access.

    Pediatric clinics of North America·2026
    Same journal

    No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

    Pediatric clinics of North America·2026
    Same journal

    Telemedicine and Access to Pediatric Dermatology Care.

    Pediatric clinics of North America·2026
    Same journal

    Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

    Pediatric clinics of North America·2026
    Same journal

    Medical Photography's Power to Change Medical Care.

    Pediatric clinics of North America·2026
    See all related articles

    Area of Science:

    • Mycology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Systemic fungal infections pose significant therapeutic challenges.
    • A range of antifungal agents are available, each with specific indications and limitations.
    • Optimizing antifungal therapy requires careful consideration of drug efficacy, toxicity, and resistance patterns.

    Purpose of the Study:

    • To review the current landscape of antifungal agents for systemic fungal infections.
    • To delineate the roles of Amphotericin B (AmB), miconazole, ketoconazole, and 5-fluorocytosine (5-FC) in clinical practice.
    • To provide guidance on the appropriate selection of antifungal therapies based on clinical scenarios.

    Main Methods:

    • Literature review of clinical studies and guidelines on antifungal drug use.

    Related Experiment Videos

  • Analysis of pharmacokinetic and pharmacodynamic properties of key antifungal agents.
  • Evaluation of clinical evidence for efficacy and safety of AmB, miconazole, ketoconazole, and 5-FC.

    • Main Results:

    • Amphotericin B (AmB) is established as the first-line agent for most systemic fungal infections.
    • Miconazole is recommended for patients intolerant to AmB or with AmB-resistant fungi.
    • Ketoconazole presents a non-toxic oral option for chronic, non-life-threatening fungal infections, though its use is limited by clinical experience.
    • 5-fluorocytosine (5-FC) is indicated solely in combination with AmB for treating yeast infections.

    Conclusions:

    • Antifungal drug selection must be tailored to the specific fungal pathogen, patient factors, and infection severity.
    • While AmB remains a cornerstone, alternative agents like miconazole and ketoconazole have defined roles.
    • Further clinical data is needed to fully establish the utility of miconazole and ketoconazole beyond specific indications.